BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23056589)

  • 1. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer.
    Sethi G; Pathak HB; Zhang H; Zhou Y; Einarson MB; Vathipadiekal V; Gunewardena S; Birrer MJ; Godwin AK
    PLoS One; 2012; 7(10):e47086. PubMed ID: 23056589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTN signaling: Components and mechanistic insights in human ovarian cancer.
    Sethi G; Kwon Y; Burkhalter RJ; Pathak HB; Madan R; McHugh S; Atay S; Murthy S; Tawfik OW; Godwin AK
    Mol Carcinog; 2015 Dec; 54(12):1772-85. PubMed ID: 25418856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
    Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; Tien JC; Rangel R; Hashimoto K; Mabuchi S; Sawada K; Kimura T; Copeland NG; Jenkins NA
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7301-E7310. PubMed ID: 28811376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer.
    Chen YF; Wang SY; Yang YH; Zheng J; Liu T; Wang L
    Int J Mol Med; 2017 Jun; 39(6):1564-1570. PubMed ID: 28487934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
    Pathak HB; Zhou Y; Sethi G; Hirst J; Schilder RJ; Golemis EA; Godwin AK
    PLoS One; 2015; 10(12):e0144126. PubMed ID: 26637171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.
    Faddaoui A; Sheta R; Bachvarova M; Plante M; Gregoire J; Renaud MC; Sebastianelli A; Gobeil S; Morin C; Ghani K; Bachvarov D
    Cell Cycle; 2017 Apr; 16(7):693-706. PubMed ID: 28278050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
    Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
    Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
    Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
    Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAP1 is overexpressed in human epithelial ovarian cancer and promotes cell proliferation.
    Hua M; Yan S; Deng Y; Xi Q; Liu R; Yang S; Liu J; Tang C; Wang Y; Zhong J
    Int J Mol Med; 2015 Apr; 35(4):941-9. PubMed ID: 25652936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
    Zhang W; Wu FX; Wang Q; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long Noncoding RNA CCAT2 Knockdown Suppresses Tumorous Progression by Sponging miR-424 in Epithelial Ovarian Cancer.
    Hua F; Li CH; Chen XG; Liu XP
    Oncol Res; 2018 Mar; 26(2):241-247. PubMed ID: 28550684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.
    Zhang L; Li Z; Gai F; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3107-14. PubMed ID: 25955305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.
    Mercier PL; Bachvarova M; Plante M; Gregoire J; Renaud MC; Ghani K; Têtu B; Bairati I; Bachvarov D
    Mol Oncol; 2011 Oct; 5(5):438-53. PubMed ID: 21856257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression.
    Barger CJ; Zhang W; Hillman J; Stablewski AB; Higgins MJ; Vanderhyden BC; Odunsi K; Karpf AR
    Oncotarget; 2015 Sep; 6(29):27613-27. PubMed ID: 26243836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncSOX4 serves an oncogenic role in the tumorigenesis of epithelial ovarian cancer by promoting cell proliferation and inhibiting apoptosis.
    Liu Y; Wang Y; Yao D; Cui D
    Mol Med Rep; 2018 Jun; 17(6):8282-8288. PubMed ID: 29693704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.